Epigenomics AG - Company Profile
Powered by 
All the data and insights you need on Epigenomics AG in one report.
$295
- Save hours of research time and resources with
our up-to-date Epigenomics AG Strategy Report
- Understand Epigenomics AG position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi proLung, a validating test for the diagnosis of lung cancer. It’s molecular diagnostic products are based on its proprietary methylation technology, which is based on a biological phenomenon called DNA methylation. The company also offers Epi BiSKit, a pre-analytical kit for the preparation of bisulfite-converted DNA, and HCCBloodTest for the detection of hepatocellular carcinoma (HCC). Epigenomics is headquartered in Berlin, Germany.
Headquarters
Germany
Address
Geneststrasse 5, Berlin, Baden-Wurttemberg, 10829
Website
www.epigenomics.com
Telephone
49 30 243450
No of Employees
18
Industry
Medical Equipment
Ticker Symbol & Exchange
ECX1 (FRA)
Revenue (2022)
$510,000
-92.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-395.2%
(2022 vs 2021)
Market Cap*
$1.5M
Net Profit Margin (2022)
XYZ
-6,234.1%
(2022 vs 2021)
* As of and is in US$
Epigenomics AG premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Epi proColon - Colorectal Cancer Screening Test | Formulate Biomarker Concepts and Strategies |
| Epi proLung - Lung Cancer Screening Test | Discover and Validate DNA Methylation (Epigenetic) Biomarkers |
| Epi BiSKit- Kit for the preparation of bisulfite-converted DNA | Obtain Regulatory Approvals |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In September, the company secured approval from the Extraordinary General Meeting on the agreement of the acquisition of assets with New Day Diagnostics LLC. |
| 2019 | Regulatory Approval | In May 2019, Centers for Medicare & Medicaid Services accepted Epigenomics application for NCD review of Epi proColon. |
| 2018 | Regulatory Approval | In October 2018, the company obtained CE mark for its liquid biopsy test “HCCBloodTest” for liver cancer detection. |
Competitor Comparison
| Key Parameters | Epigenomics AG | F. Hoffmann-La Roche Ltd | Bayer AG | Thermo Fisher Scientific Inc | Becton Dickinson and Co |
|---|---|---|---|---|---|
| Headquarters | Germany | Switzerland | Germany | United States of America | United States of America |
| City | Berlin | Basel | Leverkusen | Waltham | Franklin Lakes |
| State/Province | Baden-Wurttemberg | - | Nordrhein-Westfalen | Massachusetts | New Jersey |
| No. of Employees | 18 | 103,613 | 100,873 | 130,000 | 77,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jens Ravens | Chief Financial Officer | Senior Management | 2022 | - |
| Albert Weber | Executive Vice President - Finance | Senior Management | 2018 | - |
| Alexander Link | Director | Non Executive Board | 2020 | - |
| Heikki Lanckriet | Director | Non Executive Board | 2022 | - |
| Helge Lubenow | Director | Non Executive Board | 2016 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer